EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up

Mohammadreza Salehi, Ilad Alavi Darazam, Alireza Nematollahi, Masoumeh Alimohammadi, Sedigheh Pouya, Reza Alimohammadi, Nasim Khajavirad, Meysam Porgoo, Mosslim Sedghi, Mohammad Mahdi Sepahi, Maryam Azimi, Hamed Hosseini und 3 weitere

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112192 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Mohammadreza Salehi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehra…. Hauptthemen laut MEDLINE: Immunization, Secondary, COVID-19 Vaccines, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recurrent COVID-19 infection, despite global vaccination, highlights the need for booster doses. A heterologous booster has been suggested to enhance immunity and protection against emerging variants of concern of the SARS-CoV-2 virus. In this report, we aimed to assess the safety, and immunogenicity of COReNAPCIN, as a fourth booster dose after three doses of inactivated vaccines. METHODS: The study was conducted as a double-blind, randomized, placebo-controlled phase 1 clinical trial of the mRNA-based vaccine candidate, COReNAPCIN. The vaccine was injected as a heterologous booster in healthy Iranian adults aged 18-50 who had previously received three doses of inactivated SARS-CoV-2 vaccines. In the study, 30 participants were randomly assigned to receive either COReNAPCIN in two different doses (25 µg and 50 µg) or placebo. The vaccine candidate contained mRNA encoding the complete sequence of the pre-fusion stabilized Spike protein of SARS-CoV-2, formulated within lipid nanoparticles. The primary endpoint was safety and the secondary objective was humoral immunogenicity until 6 months post-vaccination. The cellular immunogenicity was pursued as an exploratory outcome. RESULTS: COReNAPCIN was well tolerated in vaccinated individuals in both doses with no life-threatening or other serious adverse events. The most noticeable solicited adverse events were pain at the site of injection, fatigue and myalgia. Regarding the immunogenicity, despite the seroprevalence of SARS-CoV-2 antibodies due to the vaccination history for all and previous SARS-CoV-2 infection for some participants, the recipients of 25 and 50 µg COReNAPCIN, two weeks post-vaccination, showed 6·6 and 8·1 fold increase in the level of anti-RBD, and 11·5 and 21·7 fold increase in the level of anti-spike antibody, respectively. The geometric mean virus neutralizing titers reached 10.2 fold in the 25 µg group and 8.4 fold in 50 µg group of pre-boost levels. After 6 months, the measured anti-spike antibody concentration still maintains a geometric mean fold rise of 2.8 and 6.3, comparing the baseline levels in 25 and 50 µg groups, respectively. Additionally, the significant increase in the spike-specific IFN-ϒ T-cell response upon vaccination underscores the activation of cellular immunity. CONCLUSION: COReNAPCIN booster showed favorable safety, tolerability, and immunogenicity profile, supporting its further clinical development (Trial registration: IRCT20230131057293N1).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunization, SecondaryCOVID-19 VaccinesSARS-CoV-2COVID-19Antibodies, ViralHumansAdultMaleDouble-Blind MethodFemaleIranYoung AdultMiddle AgedImmunogenicity, VaccineSpike Glycoprotein, CoronavirusAntibodies, NeutralizingmRNA VaccinesAdolescentFollow-Up Studies

Stichwörter der Autor:innen

COVID-19Heterologous boosterPhase 1 clinical trialSARS-CoV-2mRNA Vaccine

Substanzen

COVID-19 VaccinesAntibodies, ViralSpike Glycoprotein, CoronavirusAntibodies, NeutralizingmRNA Vaccinesspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: mr-salehi@sina.tums.ac.ir.
  • Department of Infectious Diseases, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical S…
  • ReNAP Therapeutics, Tehran, Iran.
  • Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Medical Affairs, Pharmed Pajoohan Viera, Tehran, Iran.
  • Clinical Trial Center, Tehran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Salehi, M., Alavi Darazam, I., Nematollahi, A., Alimohammadi, M., Pouya, S., Alimohammadi, R., Khajavirad, N., Porgoo, M., Sedghi, M., Mahdi Sepahi, M., Azimi, M., Hosseini, H., Mahmoud Hashemi, S., Dehghanizadeh, S., & Khoddami, V. (2024). Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112192

Vancouver

Salehi M, Alavi Darazam I, Nematollahi A, Alimohammadi M, Pouya S, Alimohammadi R, et al. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112192

BibTeX
@article{Salehi2024,
  author = {Salehi, Mohammadreza and Alavi Darazam, Ilad and Nematollahi, Alireza and Alimohammadi, Masoumeh and Pouya, Sedigheh and Alimohammadi, Reza and Khajavirad, Nasim and Porgoo, Meysam and Sedghi, Mosslim and Mahdi Sepahi, Mohammad and Azimi, Maryam and Hosseini, Hamed and Mahmoud Hashemi, Seyed and Dehghanizadeh, Somaye and Khoddami, Vahid},
  title = {Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112192}
}
Kostenlos starten →